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Abstract 
Ca2+-and calmodulin-dependent protein kinase III (CaM PKIII) phosphorylates ukaryotic elongation factor 2 (eEF-2) in HL-60 cells. 
Dephosphorylation f the factor in these cells is catalyzed by phosphoprotein phosphatase 2A alone. Differentiation of the HL-60 cells by 
all-trans retinoic acid resulted in a reduced growth rate and a marked decrease in the intracellular concentration of eEF-2. During 
differentiation the activity of tile eEF-2 kinase is gradually reduced and reaches 10% of that found in undifferentiated cells 5 days after 
the onset of differentiation. The capacity to dephosphorylate phospho-eEF-2 remained unaltered in the growth-arrested cells. Differentia- 
tion without reduced proliferation was induced in the HL-60 cells by interferon-3,. Under these conditions, differentiation had no effect on 
the cellular content of eEF-2 or the ability to dephosphorylate phospho-eEF-2. However, the differentiated cells showed a dramatic 
decrease in the specific activity of the eEF-2 kinase. The results show that the cellular content of eEF-2 varies with the rate of 
proliferation and that the activity of the eEF-2 kinase is high in undifferentiated proliferating cells and decreases upon differentiation even 
under conditions of an unaltered growth rate. 
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1. Introduction 
The rate of protein synthesis in eukaryotes is regulated 
in response to variations iin the growth conditions [1]. 
Translational regulation can be mediated via reversible 
phosphorylation of several of the translational factors [2]. 
One of the factors that are phosphorylated uring the 
mitotic response is eukaryodc elongation factor 2 (eEF-2) 
[3,4]. Elongation factor 2 facilitates translocation of pep- 
tidyl-tRNA from the ribosomal A-site to the P-site (for a 
review see Ref. [5]). Phosphorylation of eEF-2 reduces the 
affinity of the factor for the: ribosome, thereby decreasing 
the rate of protein synthesis [5,6]. The translational activity 
of the phosphorylated factor can be restored by the action 
of phosphoprotein phosphatases 2A and 2C (PP2A and 
PP2C, respectively) [7-9]. 
Abbreviations: CaM PKIII, Ca 2÷ and calmodulin-dependent protein 
kinase 2; DTr, dithiothreitol; eEF-2, eukaryotic elongation factor 2; 
EDTA, ethylenedinitrilo tetra acetic acid; EGTA, [ethylenebis(oxyethy- 
lenenitrilo)]tetra acetic acid; FBS, fetal bovine serum; NBT, nitroblue 
tetrazolium; NSE, nonspecific esterase; OA, okadaic acid; PP2A and 
PP2C, phosphoprotein phosphatases 2A and 2C, respectively; RA, all 
trans retinoic acid; SDS, sodium dodecyl sulphate. 
* Corresponding author. Fax: +46 8 159837. 
0167-4889/95/$09.50 © 1995 El,;evier Science B.V. All rights reserved 
SSDI 0167-4889(95)00084-4  
Elongation factor 2 is phosphorylated atThr 56 [10] by a 
specific Ca 2÷- and calmodulin-dependent protein kinase 
(CaM PKIII) [5,6,11,12]. As the activity of CaM PKIII  is 
dependent on Ca 2+, eEF-2 phosphorylation is stimulated 
by drugs that increase the intracellular concentration of 
Ca 2+, i.e., ionophores and mitogens such as vasopressin, 
bradykinin and glia maturation factor [3,13]. In addition 
Bagaglio et al. reported that phosphorylation of eEF-2 
differ between malignant and normal glia cells [14]. The 
activity of the eEF-2 kinase and the cellular content of 
phospho-eEF-2 has been found to vary during the cell 
cycle [15,16], suggesting a regulatory role for eEF-2 phos- 
phorylation in cell growth. 
Certain tumour cell lines can be induced to differentiate 
from a proliferating immature cell to a non-proliferating 
mature cell. The promyelocytic HL-60 cells can differenti- 
ate to granulocytes or monocytes in the presence of a 
variety of agents. Inducers such as interferon-y, tetrade- 
canoylphorbolester and vitamin D 3 induce monocyte dif- 
ferentiation while exposure to dimethylsulfoxide or retinoic 
acid (RA) induces HL-60 cells to undergo terminal differ- 
entiation to granulocytes [17-20]. 
In this report we have investigated the influence of 
proliferation and differentiation on the enzymatic activities 
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regulating phosphorylation a d dephosphorylation of eEF-2 
in HL-60 cells. 
2. Materials and methods 
2.1. Materials 
[y-32p]ATP and [14C]NAD+ were from Amersham In- 
ternational (UK). Calmodulin (CAM) and interferon-y was 
from Boehringer Mannheim, (Germany). All trans-retinoic 
acid (RA), nitroblue tetrazolium (NBT) and nonspecific 
esterase (NSE) kits were from Sigma Chemicals (St. Louis, 
MO. USA). Okadaic acid was a gift from Dr. Y. Tsukitani 
(Fujisawa Pharmaceuticals, Tokyo, Japan). RPMI-1640 and 
fetal bovine serum (FBS) were from GIBCO BRL Life 
Technologies, Paisley, Scotland. eEF-2 was purified from 
rat liver as previously described [21]. 
2.2. Cell culture 
HL-60 cells were grown in suspension cultures in 
RPMI-1640 supplemented with 10% FBS and antibiotics 
(100 /zg/ml streptomycin and 100 U/ml  penicillin). The 
cells were kept at 37°C in a humidified atmosphere con- 
taining 5% CO 2. Viability was estimated using the Trypan 
blue dye exclusion method. Exponentially-growing cells 
were pelleted by centrifugation a d re-suspended in growth 
medium at a cell density of 6 × 105 cells/ml. 
For differentiation, the cells were grown in the presence 
of RA (final concentration 1 /zM) for 5 days. Alterna- 
tively, the cells were allowed to differentiate in a medium 
containing 1000 units/ml interferon-y and 1 nM RA. The 
extent of differentiation was determined using the NBT 
and NSE analysis methods described by Collins [18] and 
by Yam et al. [22], respectively. Cells were stained with 
Wright-Giemsa for morphological ssessment [17]. 
2.3. Preparation of tissue homogenates 
2.4. Determination of eEF-2 content 
The eEF-2 content was determined by incubation of 
samples (final volume 100 /zl) in Buffer A containing 100 
/zg protein from cell the homogenates, 2.4 /zg diphtheria 
toxin and 75 /zM [14C]NAD+ [26]. After incubation for 30 
min at 37°C, the reactions were stopped by addition of 
cold 10% (mass/vol) trichloroacetic a id. The precipitates 
were collected and treated as previously described [27]. 
2.5. Determination of kinase activity 
The specific activity of the eEF-2 kinase in the different 
cell lysates were essentially determined as previously de- 
scribed [5]. Briefly, samples (final volume 50 /xl) contain- 
ing cell homogenates, 20 ~g protein if not otherwise 
indicated, were incubated in a buffer containing 100 mM 
KCI, 20 mM Tris-HC1 (pH 7.6), 6 mM 2-mercaptoethanol, 
10 mM MgC12, 1.0 mM EGTA, 1.5 mM Ca 2+, 0.07 mM 
EDTA, 7% (by vol.) glycerol, 0.25 mM [y-32p]ATP (spec. 
act. 280 Ci/mol), 120 pmol CaM, 1 /zmol eEF-2 and 0.3 
/zM okadaic acid. The reaction mixtures were incubated at 
37°C for 5 min and the reaction was stopped by addition of 
SDS gel electrophoresis ample buffer [28]. 
2.6. Determination of eEF-2 dephosphorylation 
The reaction mixtures contained, in final volumes of 
150 /zl, 26 /xg [32p]PO4-1abelled eEF-2, 60 /zg protein 
from the cell homogenates, 100 mM KC1, 20 mM Tris-HC1 
(pH 7.6), 6 mM 2-mercaptoethanol, l0 mM MgC12, 1.0 
mM EGTA and 1.5 mM Ca 2+. The samples were incu- 
bated at 37°C. Aliquotes of 30 /zl were spotted on filter 
paper and the papers were placed in cold 10% (weight by 
volume) trichloroacetic acid (TCA) containing 1% (by 
volume) phosphoric acid for 30 min. The papers were 
washed with 5% TCA, followed by 95% ethanol, dried and 
counted in a liquid scintillation counter. 
Rabbit reticulocyte lysates and rat liver homogenates 
were prepared as described by Nyg~rd and Hultin [23], and 
by Morley and Jackson [24], respectively. Rat brains were 
homogenized in a medium containing 70 mM Mops/KOH 
(pH 7.2), 45 mM KC1, 1 mM MgC12, 1 mM EGTA, 10 
mM NaC1 and 2 mM DTT using a Dounce homogenizer. 
The homogenized samples were centrifuged for 15 min at 
20 000 × gav and the supernatants were collected. 
Cultured cells were pelleted by centrifugation, washed 
repeatedly with PBS and suspended at equal concentration 
of cells/ml in Buffer A (100 mM KC1, 20 mM Tris-HCl 
[pH 7.6], 0.07 mM EDTA, 10% (by vol.) glycerol and 15 
mM 2-mercaptoethanol). The cells were lysed by sonica- 
tion and the samples centrifuged for 10 min at 100000 X 
gav" The supernatants were collected and the protein con- 
centrations determined [25]. The samples were stored in 
aliquotes at - 80°C. 
2.7. Gel electrophoresis 
SDS gel electrophoresis was according to Laemmli [28] 
using 7-15% (by weight)polyacrylamide gradient slab 
gels. The gels were stained with Coomassie brilliant blue, 
dried and exposed to X-ray films at -80°C using an 
intensifying screen. 
3. Results 
When purifying the eEF-2 kinase, we noticed that the 
kinase activity varied considerably between different is- 
sues. A more systematic nvestigation of the kinase activity 
in reticulocytes, myoblasts, brain and liver showed that 
homogenates from myoblast L6 cells contained the highest 
specific activity of the eEF-2 kinase (Fig. 1), while the 
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Fig. 1. Specific activity of the eEF-2 kinase in cell extracts from 
myoblasts (lane 1), reticulocytes (lane 2), liver (lane 3) and brain (lane 4). 
Kinase activity was determined as described in Section 2 using 20 Ixg 
protein from the various cell extracts. 
lowest activity was found in homogenates from rat brain. 
An analysis of the capacity of the cell homogenates to
dephosphorylate phospho-eEF-2 showed that the okadaic 
acid (OA) -sensitive phosphoprotein phosphatase PP2A 
was the main phosphatase r sponsible for dephosphorylat- 
ing the factor (Table 1). However, liver and brain ho- 
mogenates showed a considerable Mg2+-dependent activ- 
ity, indicating that PP2C contributed to dephosphorylation 
of phospho-eEF-2 in these tissues. 
The observed variations in the specific activity of the 
eEF-2 kinase prompted us to see if the activity of the 
kinase could be correlated to the rate of proliferation of the 
cells or if the activity followed the extent of differentia- 
tion. In these studies we used promyelocytic HL-60 cells, a 
turnout cell line that can 1be induced to differentiate to 
granulocytes when the cells are grown for 5 to 6 days in 
the presence of retinoic acid (RA) [17-20]. Five days after 
introduction of RA in the growth medium, more than 90% 
of the cells had differentiated past the promyelocyte stage 
as judged by morphological criteria [17] and by the ability 
to reduce NBT [18]. The differentiation was also accompa- 
nied by a complete inhibition of the cell growth manifested 
Table 1 
Effects of EDTA and okadaic acid (OA) on dephosphorylation of eEF-2 
Source Phospho-eEF-.2 dephosphorylated 
pmol X min- J × mg-  i protein 
Control + OA + EDTA + OA 
Brain 260 120 0 
Liver 120 48 6 
Reticulocytes 110 0 0 
Myoblasts 250 0 0 
HL-60 cells 180 0 0 
310 !iiil 
Fig. 2. Effect of differentiation on the specific activity of the eEF-2 
kinase. Cell extracts from HL-60 cells grown under control conditions 
(lane 1) and in the presence of retinoic acid (lane 2) or interferon-), (lane 
3) were analyzed for CaM PK III activity as described in Section 2 using 
20 p,g protein from the various cell extracts. 
already 24 h after inclusion of RA in the growth medium 
(Fig. 3). These observations are in agreement with previ- 
ous reports [17]. 
Analysis of the eEF-2 kinase activity in the HL-60 cells 
showed that the undifferentiated cells contained a high 
specific activity of the enzyme (Fig. 2). The activity was 
comparable to that observed in myoblasts and reticu- 
locytes. However, growth in RA containing medium re- 
suited in a conspicuous decrease of the eEF-2 kinase 
activity. The decrease in kinase activity could be detected 
already 24 h after introduction of RA in the medium and 
was progressively decreasing to 10% of that found in 
control cells after 5 days treatment (Fig. 3). These results 
show that the decrease in kinase activity is an early 
response to RA and that the kinase activity is progressively 
decreased during the RA treatment. Analysis of the amount 
of eEF-2 in these cells showed that eEF-2 content was 
reduced by 50% after 5 days in RA-containing medium 
(Table 2). The HL-60 cells can be induced to differentiate 
to monocytes without reducing the rate of proliferation by 
growing the cells in a medium containing interferon-'y 
[29]. The effect of interferon-0, is synergistically increased 
by low concentrations of RA [30]. Five days treatment 
with interferon-7 in combination with RA resulted in a 
differentiation f more than 80% of the cells as determined 
both morphologically and by NBT and NSE measure- 
ments. At the same time proliferation was virtually unaf- 
fected (Table 2 and Fig. 3) [30]. An analysis of the eEF-2 
kinase activity showed that the specific activity was re- 
duced to 11% of that seen in the undifferentiated cells after 
5 days growth in the presence of interferon-% Hence, the 
reduction in kinase activity was similar to that observed in 
cells treated for the same period with RA alone (Fig. 3). 
This suggests that differentiation could lead to a reduction 
in the kinase activity even in the absence of a reduced rate 
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Fig. 3. Cell proliferation (A) and specific activity of the eEF-2 kinase (B) 
in HL-60 cells grown in the presence of retinoic acid (0 )  or interferon-',/ 
(~r). Control cells (0) .  Viable cell count were determined using trypan 
blue exclusion. Kinase activity were assayed as described in Section 2 
using 20 /zg protein from the cellular homogenates. 
o~" 100LO 
 .ol 
v v v 
40 
20 
0 0 
I I i I , I , I 
2 4 6 8 10 
Time (minutes) 
Fig. 4. Dephosphorylation of phospho eEF-2. Phospho-eEF-2 was 
dephosphorylated in the presence of cell homogenates, as described in 
Section 2, from HL-60 grown under control conditions (0 )  or in the 
presence of ( • ) RA or interferon-'/ ( • ). 
addition of OA to the homogenates resulted in a slight 
increase in the extent of eEF-2 phosphorylation (Table 2). 
A comparison of the dephosphorylating capacity in undif- 
ferentiated and RA-or interferon-y-treated cells showed 
that the rate of dephosphorylation f phospho-eEF-2 was 
similar in all cell preparations (Fig. 4). We therefore 
conclude that the observed ecrease of eEF-2 phosphoryla- 
tion in differentiated cells was not due to an increased 
phosphatase activity but rather to a decrease in eEF-2 
kinase activity. 
of proliferation. The interferon-y induced differentiation 
was not associated with any decrease in the intracellular 
concentration of eEF-2 (Table 2). Thus, when these cells 
are induced to terminal differentiate by interferon-y at a 
concentration ot effecting the proliferation, the eEF-2 
concentration remains the same as in the untreated cells. 
As seen in Table 1, dephosphorylation of phospho-eEF-2 
in HL-60 cells was catalyzed by the OA-sensitive PP2A. 
Also in differentiated HL-60 cells eEF-2 was exclusively 
dephosphorylated by PP2A (results not shown). Hence, 
Table 2 
Effect of retinoic acid (RA) and interferon-7 on proliferation, cellular 
content of eEF-2 and specific activity of the EF-2 kinase 
Cells eEF-2 Kinase 
× 10-6/ml  /zg/mg protein activity 
(%) (%) (%) 
- +OA 
Control 2.7 (100) 1.40 (100) 100 123 
RA 1.4 (40) 0.75 (53) 8 12 
RA + y 2.6 (96) 1.25 (89) I 1 19 
4. Discussion 
Proliferating cells require a substantial translational c- 
tivity for the de novo synthesis of cellular components. 
Alterations in the rate of proliferation are reflected by 
changes in the activity of the translational machinery 
[31-33]. When quiescent cells are growth-stimulated by
serum or mitogens the rate of protein synthesis is increased 
two-to three-fold [33-35]. This increase is in part caused 
by the recruitment of a large pool of pre-existing non-poly- 
some-bound mRNA to actively translating polysomes [32]. 
In addition, there is also an increase in the content of 
translational components such as ribosomes and eEF-1 ce 
[32,36,37]. After inhibition of the proliferation, there is a 
reduced demand for new proteins and the translational 
machinery subsequently adapts to the new situation. This 
can be seen in proliferation-arrested HL-60 cells where the 
intracellular concentration of eEF-2 is reduced to about 
50% of that found in growing cells. 
Protein synthesis also shows a cell cycle-dependent 
variation. During mitosis the rate of translation is de- 
creased compared to that observed uring the interphase 
[38]. The reduction has been attributed to an inhibition at 
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the initiation step in protein synthesis [38] but a reduced 
elongation rate has also been suggested [16]. The latter 
suggestion was based on the observation that the cellular 
content of phospho-eEF-2, a translationally inactive form 
of the factor [5,39], increases during mitosis [16]. 
Elongation factor 2 is phosphorylated by a specific 
Ca2÷-and calmodulin-dependent protein kinase [3,6]. The 
phosphorylation is stimulated by mitogens uch as vaso- 
pressin and glia maturation factor [3,13]. In addition it was 
recently shown that malignant glioma cells contain higher 
eEF-2 kinase activity than normal glia cells [14]. These 
results suggest hat the eEF-2 kinase activity is higher in 
proliferating cells than in non-proliferating cells. The ob- 
servation that growing HL-60 cells show approximately 10 
times higher eEF-2 kinase activity than the corresponding 
growth-arrested cells is in line with this suggestion. How- 
ever, as growth inhibition in the HL-60 cells was induced 
by introducing RA in the growth medium, the decreased 
rate of proliferation was also associated with differentia- 
tion of the cells [17]. Thus, the observed ecrease in eEF-2 
kinase activity could originate from the differentiation 
process rather than the reduced rate of proliferation. To 
avoid differentiation coupled to an inhibition of prolifera- 
tion, we induced differentiation by treating the cells with 
interferon-y. Under these e~perimental conditions, HL-60 
cells differentiate to monocytes without any alteration in 
the rate of proliferation [30]. The eEF-2 kinase showed 
approximately 15% of the activity found in the undifferen- 
tiated control cells while the ability to dephosphorylate 
phospho-eEF-2 was unchanged. These data show that the 
eEF-2 kinase activity is reduced upon differentiation f the 
HL-60 cells. Interestingly, the eEF-2 content is not af- 
fected by the differentiation process unless the growth rate 
is altered. Thus, the eEF-2 kinase activity does not co-vary 
with the content of its substrate, EF-2, in the HL-60 cells. 
Although the results presented here suggest hat the 
specific activity of the eEF-2 kinase is controlled by the 
differentiation process in HL-60 cells, we cannot rule out 
the possibility that the activity of the eEF-2 kinase could 
be decreased in a situation where growth but not differenti- 
ation is altered. In this context it is important to remember 
that results obtained in one cell type cannot be generalized 
to other cells. Various cell types respond ifferently to the 
same type of stimulus. For example, when HL-60 cells are 
stimulated with interferon- T they differentiate without any 
growth arrest [30]. In contrast, keratinocytes treated with 
interferon-7 show a dramatic reduction in growth rate [40]. 
Hence, the observed effect of interferon-~/ on differentia- 
tion, proliferation and the activity of the eEF-2 kinase may 
only be valid for HL-60 cells. 
Why do undifferentiated growing cells contain higher 
eEF-2 kinase activity than growth-arrested or differentiated 
cells? Clearly the results presented here do not provide an 
answer to this question. During mitosis protein synthesis i  
stopped and the level of phosphorylated EF-2 increases 
[16,38]. It has therefore been suggested that phosphoryla- 
tion of eEF-2 is directly involved in the observed transla- 
tional arrest [4,16]. If mitosis is associated with a reduced 
rate of elongation caused by eEF-2 phosphorylation, cells 
that frequently divide should be expected to have a high 
capacity to phosphorylate eEF-2. However, reticulocytes 
which do not divide but are not yet terminally differenti- 
ated to mature rythrocytes have high CaM PKIII activity. 
Furthermore, HL-60 cells differentiated to monocytes by 
interferon-y treatment do proliferate but have low CaM 
PKIII activity. Direct measurements of the eEF-2 kinase 
activity during different stages of the cell cycle in Ehrlich 
ascites tumour cells show that the kinase activity peaks in 
early S-phase rather than in the M-phase [15]. Taken 
together these observations indicate that high eEF-2 kinase 
activity is not always dependent on a high mitotic fre- 
quency. 
Phosphorylated eEF-2 is inactive in protein synthesis 
[5,6]. It may therefore seem surprising that the capacity to 
phosphorylate and thereby to inactivate EF-2 is highest 
during conditions where there is an extensive need for de 
novo synthesis of proteins. A high kinase activity mani- 
fested in vitro does not necessarily mean that the kinase is 
active under in vivo conditions where activity may be 
controlled by different activators and inhibitors [41-45]. 
However, it has been shown that the majority of eEF-2 has 
to be phosphorylated before any effect on the translation 
rate can be detected [8]. Thus, the high phosphorylating 
capacity found in undifferentiated growing cells may allow 
a rapid phosphorylation of sufficient amounts eEF-2 to 
cause a transient block in the elongation cycle under 
certain physiological conditions. Inhibition of the elonga- 
tion cycle stimulates translation of certain mRNAs [46-50], 
suggesting that phosphorylation f eEF-2 causes a transla- 
tional advantage for mRNAs that are bad competitors for 
the translational initiation machinery [51]. Such a mecha- 
nism for regulating the translation of specific mRNAs may 
be involved in regulating proliferation and differentiation 
in growing undifferentiated cells. 
Acknowledgements 
o 
We are grateful to A. Bergstr~Sm and B. Lundberg for 
technical assistance. We are indebted to Prof. U. Lindberg 
for generous upport. This work was supported by the 
Swedish Natural Science Research Council grant B-Bu 
8463-307. 
References 
[1] Kozak, M. (1992) Annu. Rev. Cell Biol. 8, 197-225. 
[2] Hershey, J.W.B. (1991) Annu. Rev. Biochem. 60, 717-755. 
[3] Palfrey, C.H., Nairn, A.C., Muldoon, L.L. and Villereal. M.L. 
(1987) J. Biol. Chem. 262, 9785-9792. 
[4] Abdelmajid, H., Leclerc-David, C., Moreau, M., Guerrier, P. and 
Ryazanov, A. (1993) Int. J. Dev. Biol. 37, 279-290. 
268 A. Nilsson, O. Nyghrd/ Biochimica et Biophysica Acta 1268 (1995) 263-268 
[5] Carlberg, U., Nilsson, A. and Nyg~d, O. (1990) Eur. J. Biochem. 
191,639-645. 
[6] Ryazanov, A.G., Shestakova, E.A. and Natapov, P.G. (1988) Nature 
334, 170-173. 
[7] Gschwendt, M., Kittstein, W., Mieskes, G. and Marks, F. (1989) 
FEBS Lett. 257, 357-360. 
[8] Redpath, N.T. and Proud, C.G. (1989) Biochem. J. 262, 69-75. 
[9] Redpath, N.T. and Proud, C.G. (1990) Biochem. J. 272, 175-180. 
[10] Price, N.T., Redpath, N.T., Severinov, K.V., Campbell, D.G., Rus- 
sel, J.M. and Proud, C.G. (1991) FEBS Lett. 282, 253-258. 
[11] Nairn, C.A., Bhagat, B. and Palfrey, C.H. (1985) Proc. Natl. Acad. 
Sci. USA 82, 7939-7943. 
[12] Redpath, N.T. and Proud, C.G. (1993) Eur. J. Biochem. 212, 
511-520. 
[13] Okumura-Noji, K., Kato, T., Ito, J., Suzuki, T. and Tanaka, R. 
(1990) Neurochem. Int. 17, 559-571. 
[14] Bagaglio, D.M., Cheng, E.H.C., Gorelick, F.S., Mitsui, K., Nairn, 
A.C. and Hait, W.N. (1993) Cancer Res. 53, 2260-2264. 
[15] Carlberg, U., Nilsson, A., Skog, S., Palmqvist, K. and Nyg~rd, O. 
(1991) Biochem. Biophys. Res. Commun. 180, 1372-1376. 
[16] Celis, J.E., Madsen, P. and Ryazanov, A.G. (1990) Proc. Natl. Acad. 
Sci. USA 87, 4231-4235. 
[17] Breitman, T.R., Selonick, S.E. and Collins, S.J. (1980) Proc. Natl. 
Acad. Sci. USA 77, 2936-2940. 
[18] Collins, S.J., Bodner, A., Ting, R. and Gallo, R.C. (1980) Int. J. 
Cancer 25, 213-218. 
[19] Yen, A., Brown, D. and Fishbaugh, J. (1987) Exp. Cell Res. 168, 
247-254. 
[20] Collins, S.J. (1987) Blood 70, 1233-1244. 
[21] Nilsson, L. and Nyg~d, O. (1984) Biochim. Biophys. Acta 782, 
49-54. 
[22] Yam, L.T., Li, C.Y. and Crosby, W.H. (1971) Am. J. Clin. Patho- 
physiol. 55, 283-290. 
[23] Nyg~rd, O. and Hultin, T. (1975) Chem. Biol. Interact. 21,589-598. 
[24] Morley, S.J. and Jackson, R.J. (1985) Biochem. Biophys. Acta 825, 
45-56. 
[25] Bradford, M.M. (1976) Anal. Biochem. 72, 248-254. 
[26] Honjo, T., Nishizuka, Y., Kato, T. and Hayaishi, O. (1971) J. Biol. 
Chem. 246, 4251-4260. 
[27] Nyg~rd, O. and Nilsson, L. (1984) Eur. J. Biochem. 140, 93-96. 
[28] Laemmli, U.K. (1970) Nature 227, 680-685. 
[29] Ball, E.D., Guyre, P.M., Shen, L., Glynn, J.M., Maliszewski, C.R., 
Baker, P.E. and Fanger, H. (1983) J. Clin. Invest. 73, 1072-1077. 
[30] Hemmi, H. and Breitman, T.R. (1987) Blood 69, 69. 
[31] Chaudhuri, S. and Lieberman, I. (1968) J. Biol. Chem. 243, 29-33. 
[32] Rudland, P.S., Wiel, S. and Hunter, A.R. (1975) J. Mol. Biol. 96, 
745-766. 
[33] Morley, S.J. and Thomas, G. (1991) Pharmacol. Ther 50, 291-319. 
[34] Thomas, G., Siegmann, M. and Gordon, J. (1979) Proc. Natl. Acad. 
Sci. USA 76, 3952-3956. 
[35] Thomas, G., Siegmann, M., Kubler, A., Gordon, J. and deAsaua, 
L.J. (1980) Cell 19, 1015-1023. 
[36] Jefferies, H.B.J., Thomas, G. and Thomas, G. (1994) J. Biol. Chem. 
269, 4367-4372. 
[37] Levenson, R.M., Nairn, A.C. and Blackshear, P.J. (1989) J. Biol. 
Chem. 264, 11904-11911. 
[38] Fan, H. and Penman, S. (1970) J. Mol. Biol. 50, 655-670. 
[39] Ryazanov, A.G. and Davydova, E.K. (1989) FEBS Lett. 251, 187- 
190. 
[40] Saunders, N.A. and Jette, A.M. (1994) J. Biol. Chem. 269, 2016- 
2022. 
[41] Nyg~d, O., Nilsson, A., Carlberg, U., Nilsson, L. and Amons, R. 
(1991) J. Biol. Chem. 266, 16425-16430. 
[42] Mitsui, K., Brady, M., Palfrey, H.C. and Nairn, A.C. (1993) J. Biol. 
Chem. 268, 13422-13433. 
[43] Nairn, A.C., Nichols, R.A., Brady, M.J. and Palfrey, H.C. (1987) J. 
Biol. Chem. 262, 14265-14272. 
[44] Palmqvist, K., Riis, B., Nilsson, A. and Nyg~rd, O. (1994) FEBS 
Lett. 349, 239-242. 
[45] Nairn, A.C and Palfrey, H.C. (1987) J. Biol. Chem. 262, 17299- 
17303. 
[46] Ryazanov, A.G. and Spirin, A.S. (1990) New Biol. 2, 843-850. 
[47] Svitkin, Y.V. and Agol, V.I. (1983) Eur. J. Biochem. 133, 145-154. 
[48] Walden, W.E., Godefroy-Colburn, T. and Thach, R.E. (1981) J. 
Biol. Chem. 256, 11739-11746. 
[49] Walden, W.E. and Thach, R.E. (1986) Biochemistry 25, 2033-2041. 
[50] Lodish, H.F. (1971) J. Biol. Chem. 246, 7131-7138. 
[51] Ryazanov, A.G. and Spirin, A.S. (1990) New Biol. 2, 843-850. 
